Status: Point in time view as at 26/11/2020. Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1771. (See end of Document for details)

ANNEX

Common Name	n IUPAC NameIde Number	entifikatie	m degree (Pive subst		Date of approva	Expiry date of l approva	Product type I	Specific condition	ns
mass of	peracetic acid (iPOiA) and peroxyoct acid (POOA) EC No: 201-186-8 and 450-280-7 CAS No: 79-21-0	the active not releva substance equilibriu peroxide, octanoic a	is a doubl m using hy acetic acid acid as star The speci d to a rang tion.	is ctive e ydrogen l and ting fications ge of Specificat	1 April 2022	31 March 2032	2		
		7 Active	Peracetic	range content (%w/w) 1,8–13,9					assessment shall pay particular attention to the exposures, the
		substance Active substance	Peroxyoc acid	2,42					
		Relevant impurity	Hydrogn peroxyde						ine risks and the efficacy linked
									to any uses covered by
									an application for authorisation but
									not addressed in the Union
		this column v				<u> </u>	1 (1 77)		level

a The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

of... Document Generated: 2024-07-14

Status: Point in time view as at 26/11/2020. Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1771. (See end of Document for details)

							(b)	assessment of the active substance. In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users.
	Relevant impurity	Acetic acid	5,74–51			3	The authorisa	tions
purity indicated is stance in the produ	Relevant impurity	Octanoic acid	1,63– 9,03	purity of the act	ive substance	evaluated. The	of biocidal products are subject to the following condition (a)	g

a The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

Status: Point in time view as at 26/11/2020. **Changes to legislation:** There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1771. (See end of Document for details)

						1		
							and	
							the	
							efficacy linked	
							to	
							any	
							uses	
							covered	
							by	
							an	
							application	
							for	
							authorisation,	
							but	
							not	
							addressed	
							in the	
							Union	
							level	
							assessment	
							of	
							the	
							active	
							substance.	
						(b)	In	
							view	
							of the	
							risks	
							identified	
							for	
							the	
							uses	
							assessed,	
							the	
							product	
							assessment	
							shall	
							pay particular	
							attention	
							to	
							professional	
							users.	
					4	The	_	
					1	authorisa	ations	
The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active								
substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.								
articles	Regulation (EC) No 1935/2004 of the European Parliament and of the Council of 27 October 2004 on materials and articles intended to come into contact with food and repealing Directives 80/590/EEC and 89/109/EEC (OJ L 338, 13.11.2004, p. 4).							
15.11.20	оот, р. т <i>)</i> .						_	

a

b

of... Document Generated: 2024-07-14

Status: Point in time view as at 26/11/2020. Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1771. (See end of Document for details)

of biocidal products are subject to the following conditions: (a) The product assessment shall pay particular attention to the exposures, the exposures, the efficacy linked to any uses covered by an application for authorisation, but not addressed in the efficacy linked to any uses covered by an application for authorisation, but not addressed in the efficacy linket to any uses covered by an application for eauthorisation, but not addressed in the efficacy linket covered by an application for products covered by an application for products covered by an application for products covered by an application for products covered by an authorisation, but not addressed in the but products covered by products covered by products covered by products covered by products covered by products covered by products covered by products covered by products covered by products covered by products covered by products covered by products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by but products covered by by by but products covered by by by by by by by by by by by by by				
biocidal products are subject to the following conditions: (a) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to the efficacy linked the efficacy linked the any uses covered by an application for authorisation, but not addensed in the assessment of the the efficacy linked the efficacy linked the and application for authorisation, but not addressed in the assessment of the assessment of the assest covered by an application for authorisation, but not addressed in the assessment of the assest the assest assest assest the assest the but not addressed in the assest assest but not but not addressed in the assest assest assest but not but not but not but not but not but not but not but not but not but not but not but not but not but assest assest assest assest but but not but but not but assest assest assest athe athe assest athe at			of	
products are subject to the following conditions: (a) The product assessment shall pay pay pay pay pay pay pay pay pay pay				
are subject to the following conditions: (a) The product assessment shall pay pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the ety covered by an application for authorisation, but not addressed in the ety covered by an application for authorisation, but not addressed in the ety covered by an application for authorisation, but not addressed in the ety assessment of the covered by an application for authorisation, but not addressed in the ety assessment of the				
subject to the following conditions: (a) The pay pay pay particular attention to the exposures, exposures, the exposures, exposures, the exposures, exposures, the exposures, exposures, the exposures, exposures, the exposures, exposures, the exposures, expo				
to the following conditions: (a) The product assessment shall pay pay pay pay pay pay pay pay pay pay				
following conditions: (a) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to to any uses covered by an application for authorisation, but not addressed in the the efficacy linked to to to to to to to the efficacy linked to to to to to to to the efficacy linked to to to to to to to to to to to to to			to the	
(a) The product assessment shall pay patricular attention to the exposures, the the exposures, the efficacy linked to uses covered by an application for for atthrisation, but the uses covered by an application for addressed in the the uses covered by an assessment of of the uthorisation, but uthor assessment of the uthor evel assessment of uthe assessment of the uthe assessment of the uthe astice <t< td=""><td></td><td></td><td></td><td>.</td></t<>				.
(a) The product assessment shall pay pay particular attention to the exposures, the risks and the efficacy linked to to any uses covered by an application for authorisation, but not addressed in the evel assessment of the the evel assessment of the the evel assessment of the the the evel assessment addressed in the the the the the the the the the the			andition	
product assessment shall pay particular attention to the exposures, the exposures, the exposures, the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the assessment of the products				
assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an any uses covered by an application for authorisation, but not addressed in the efficacy linked to any uses covered by an application for authorisation, but not addressed in the efficacy linked to any uses covered by but not addressed in the efficacy linked to any uses covered by but not addressed in the union level assessment of the active substance. (b) Products				
shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the the efficacy linked to to to any uses covered by y an addressed in the the the the the the the the the the				
Image: second				
particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the efficacy linked to any uses covered by an application for authorisation, but not addressed in the efficacy linked to by an application for authorisation, but not addressed in the evel assessment of the active substance.				
attention to the the exposures, the risks and the efficacy linked to to any uses covered by an application for authorisation, but not addressed in the uses assessment of the usitive substance. (b) Products				pay
to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the assessment of the uses covered by an application for authorisation, but not addressed in the Union level assessment of the assessment of the active authorisation.				particular
the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the assessment of the products				attention
exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance.				to
the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the Union level assessment of the Union level assessment of the active substance.				the
the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the Union level assessment of the Union level assessment of the active substance.				exposures,
and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				the
and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				linked
any uses covered by an application for authorisation, but not addressed in the Union level assessment of the assessment of the active substance. (b) Products				
uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
covered by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
by an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
an application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
application for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				
for authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				an
authorisation, but not addressed in the Union level assessment of the active substance. (b) Products				application
but not addressed in the Union level assessment of the active substance. (b) Products				
not addressed in the Union level assessment of the active substance. (b) Products				authorisation,
addressed in the Union level assessment of the active substance. (b) Products				
in the Union level assessment of the active substance. (b) Products				
in the Union level assessment of the active substance. (b) Products				addressed
the Union level assessment of the active substance. (b) Products				
Union level assessment of the active substance. (b) Products				
level assessment of the active substance. (b) Products				
assessment of the active substance. (b) Products				
of the active substance. (b) Products				
the active substance. (b) Products				
active substance. (b) Products				
(b) Products				
(b) Products				
(b) Products containing				
containing			(0)	
				containing

a The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

Status: Point in time view as at 26/11/2020. Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1771. (See end of Document for details)

reaction
mass
of .
peracetic
acid
and
peroxyoctanoic
acid
shall
not
be
incorporated
in
materials
and
articles
intended
to
come
into
contact
with
food
within
the
meaning
of
Article
1(1)
of
Regulation
(EČ)
No
1935/2004
of
the
European
Parliament
and
of
the
Council ^b ,
unless
the
Commission
has
established


a The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

of... Document Generated: 2024-07-14

Status: Point in time view as at 26/11/2020. Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1771. (See end of Document for details)

		specific
		limits
		on
		the
		migration
		of
		reaction
		mass
		of
		peracetic
		acid
		and
		peroxyoctanoic acid
		into food
		or
		it
		has
		established]
		in
		accordance
		with
		that
		Regulation
		that
		such
		limits
		are
		not
		necessary.
	(c)	In
		view
		of
		the
		risks
		identified
		for
		the
		uses
		assessed,
		the
		product
		assessment
		shall
		pay particular
		particular

a The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.



Status:

Point in time view as at 26/11/2020.

Changes to legislation:

There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1771.